AstraZeneca confuses investors after reporting two different efficacy rates achieved by its Covid-19 vaccine
AstraZeneca will sell its vaccine to governments at significantly lower prices as compared to Pfizer and Moderna.
avatar
Staff or Guest writer for The Dog of Wall Street.
2020-11-23 14:45

AstraZeneca PLC (NASDAQ: AZN) on Monday reported that its vaccine achieved a 70 percent efficacy rate on average in preventing the Covid-19. The results are based on the data from a late-stage trial. AZN shares fell nearly 2 percent this morning following the news.

AstraZeneca confuses investors after reporting two different efficacy rates achieved by its Covid-19 vaccine

The apparent reason behind the drop seems to be a comparatively much lower effectiveness percentage achieved by AZN’s vaccine as compared to rivals Pfizer Inc. (PFE) and Moderna Inc. (MRNA),who accomplished more than 90 percent efficacy in preventing the virus.

However, British drugmaker AstraZeneca said its vaccine was 90 percent effective when tested in a small subgroup of nearly 2,700 people in Brazil and the United Kingdom who were given a half dose followed by a full dose with a four-week interval. Though, the company achieved an efficacy rate of 62 percent after testing the vaccine on a large group of around 8,900 people, giving them two complete doses with an interval of a month.

AstraZeneca, which is developing the vaccine in collaboration with the University of Oxford, faced criticism from industry experts for reporting two different efficacy rates. However, AstraZeneca has one notable edge over its rivals. It will sell its vaccine to governments at significantly lower prices as compared to Pfizer and Moderna.

Moreover, AstraZeneca’s vaccine can be shipped and stored at normal refrigeration temperature, making it easy to distribute, particularly in developing countries. On the other hand, Pfizer’s vaccine needs to be kept at -70C. So, the company’s vaccine may do well in less developed countries.

AstraZeneca stock is currently trading on a heavy volume of 12 million shares, as compared to the daily average volume of 4.52 million shares. The stock has seen many ups and downs this year. Overall, AZN share price rose nearly 9 percent on a year-to-date basis.


Disclaimer: I have no positions in any of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article. All information should be independently verified and should not be relied upon for purposes of transacting securities or other investments. See terms for more info.

Rate this article

positive
negative
Published On
2020-11-23 14:45

avatar
About the Author
Staff or Guest writer for The Dog of Wall Street.


buy-coffee
You've read 1 article in the last year
..thank you for supporting us and for visiting our site. Unlike many other sites, The Dog of Wall Street is available for everyone to read. Our focus is to provide great content for free. Do you like what we are doing? Buy us a cup coffee. It is the fuel that keeps us going..

Levi Strauss' Bold Gambit: Is the Denim Icon's DTC Shift Enough to Weather the Storm?
Levi Strauss & Co. boasts a strong quarter with direct-to-consumer growth and innovative fashion, but can it navigate the choppy waters of the retail market?
By Alfonso | 3 months ago

Amazon's Bold Counterattack: Introducing the China-Direct Discount Section
As competition heats up, Amazon unveils a daring new strategy to offer unbeatable prices and direct shipping from China.
By Alfonso | 3 months ago

Tesla's Legal Challenges: Facing the Music on Autopilot Misrepresentation
Court ruling intensifies scrutiny on Tesla's self-driving claims.
By Alfonso | 5 months ago

Netflix's Ad-Supported Triumph: A New Era in Streaming
Surpassing 40 million users, Netflix’s ad-supported plan redefines the streaming landscape.
By Alfonso | 5 months ago

Tesla Stock (TSLA): Look Who's Back!
I’m cautiously optimistic but I’m at the point where I need to see it to believe it.
By Mike Sakuraba | 5 months ago

2 Earnings To Pay Attention to Next Week
Since big tech is the theme, you probably know what I have my eyes on for next week.
By Mike Sakuraba | 5 months ago

2 Stocks to Watch Below $10
Here are two stocks that are currently less trading in the single digits that I believe have some relative upside from their current prices.
By Mike Sakuraba | 5 months ago

Looking Ahead to Tesla's Earnings: What Can We Expect?
Is there any stock that has been more talked about than Tesla (NASDAQ: TSLA) as of late? It’s a company that is always in the spotlight but the stock is under some heavy scrutiny this year and deservedly so.
By Mike Sakuraba | 5 months ago